J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Tahtawy, A.
Right arrow Articles by Reidenberg, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Tahtawy, A.
Right arrow Articles by Reidenberg, B. E.

PEDIATRICS

Population Pharmacokinetics of Oxycodone in Children 6 Months to 7 Years Old

Ahmed El-Tahtawy, RPh, PhD, Hannu Kokki, MD and Bruce E. Reidenberg, MD

From the Metrum Research Group, Tariffville, Connecticut (Dr El-Tahtawy); the Department of Anesthesiology and Intensive Care, Kuopio University Hospital, Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland (Dr Kokki); and the Departments of Pharmacology and of Pediatrics, Weill Medical College of Cornell University, New York, New York (Dr Reidenberg).

Young children are often undertreated for pain. One barrier to effective pain treatment is understanding the pharmacokinetic behavior of analgesics in this age group. Oxycodone is a commonly prescribed opioid for severe pain, yet little is known about its pharmacokinetics in young children. This article used population pharmacokinetic modeling to synthesize pharmacokinetic data from several studies into a model. A single population model that described the observed pharmacokinetics was developed. The combined data were best described with a 2-compartment linear model with different first-order absorption rates depending on route of administration. Weight was found to significantly influence both clearance (CL) and volume of distribution (Vd). The following model adequately describes the population pharmacokinetic profile of oxycodone where absolute bioavailability (F) is estimated for each administration route: CL/F = 55 x (body weight/70)0.87; V/F= 86 x (body weight/70)1.16. The interindividual coefficients of variation in CL and Vd were 20.2 and 19.7%, respectively. This finding confirms that the allometric scaling using the above model explained most of the variability in exposure observed among children. This model confirms using a weight-based dose for oxycodone without adjustment for age between 6 months and 7 years and is valuable for evaluating dosing schedules and dosing routes.


Key Words: Opioidpediatricpharmacokinetics

Address for reprints: Bruce E. Reidenberg, MD, Departments of Pharmacology and Pediatrics, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology